anti-PON3 (Paraoxonase 3), mAb (5G11)

CHF 322.00
In stock
YIF-LF-MA0273100 µlCHF 322.00
More Information
Product Details
Synonyms PON3; EC=3.1.8.1; EC=3.1.1.2; EC=3.1.1.81; Serum Paraoxonase/Lactonase 3
Product Type Monoclonal Antibody
Properties
Clone 5G11
Isotype Mouse IgG1 κ
Immunogen/Antigen Recombinant human His-PON3 protein purified from E. coli.
Application

Western Blot (1:2,000)

Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Paraoxonases are a group of enzymes invloved in the hydrolysis of organophosphates. Paraoxon, an organophosphate, is an acetylcholinesterase inhibitor and the active metabolite of the insecticide parathion. Besides a toxicological role, clinical interest has focused on a protective role in vascular disease. Paraoxonase-1 (PON1) is a calcium-dependent ester hydrolase that is tightly associated with apoA-I in HDL. PON1 prevents the oxidation of LDL, thereby the formation of atherogenic oxidised-LDL. Polymorphisms of the human PON1 gene are correlated with coronary artery disease, indicating a genetic association between PON1 and coronary artery disease. PON1 activity is lower in subjects prone to development of atherosclerosis such as in type 1 and type 2 diabetes, familial hypercholesterolemia, and renal disease, indicating the involvement of PON1 in atherosclerosis development. PON2 is a ubiquitously expressed intracellular protein that can protect cells against oxidative damage. PON3 is similar to PON1 in activity but differs from it in substrate specificity. PON1 and PON3 are implicated in lowering the risk of developing coronary artery disease and atherosclerosis. Human PON3 protein shares the 3 conserved cysteine residues identified in PON1, suggesting their importance of in vivo activities. PON1-based catalytic scavengers can be a way to safe and effective organophosphate intoxication. Has very limited arylesterase and no paraoxonase activities but rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin). Hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents.

Product References

1) Rochu D et al. (2007) Toxicology. 233(1-3):47-59. (General)
2) Mackness M and Mackness B, (2004) Free Radic Biol Med. 37(9):1317-1323 (General)
3) Reddy ST et al. (2001) Arterioscler. Thromb. Vasc. Biol. 21(4):542–547 (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.